Board summary
Key figures
27,887
Registered population
61.1% aged 18–64
19.3%
Aged 65+
ICB 21.9% · England 17.9%
8.8%
Ethnic minority (non-White)
4.0% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 9.2% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
4,148
Hypertension register
+2.06% in 3 yrs · England +5.60%
195
SMI register
15.4% of Horsham's
331
COPD register
Reviews +8.39% in 3 yrs
Forecast to 2030
4,875
Hypertension patients, 2030
+727 on today
81.8%
QRISK ≥20% on statins, 2030
+7.66pp over 3 yrs
4.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail benchmarks and fell.
Annual reviews reached 56.5% (Horsham 62.4%, England 65.7%), falling 2.8% over 2023 to 2025 and leaving about 720 of 1,663 patients unreviewed.
Wide practice divergence on phone access and vaccines.
Easy phone contact ranges 31.5 pp from 47.0% at Riverside Medical Practice to 78.6% at Holbrook Surgery, matching a 31.5 pp QOF vaccination gap.
Lipid therapy and COPD reviews outpaced England.
Over 2023 to 2025, QRISK ≥ 20% lipid therapy rose +13.8% (England +6.2%) to 63.2%, and COPD reviews rose +8.4% to 79.2%.
Population, age and ethnicity
At 19.3%, older adult share trails Horsham despite projected 7.4% list growth
Horsham Central PCN registers 27,887 patients across Holbrook Surgery (16,417) and Riverside Medical Practice (11,470). Patients aged 65+ comprise 19.3% (5,384 patients), below Horsham (23.7%) and NHS Sussex Integrated Care Board (21.9%), but above England (17.9%). Projected list growth to 2030 is 7.4% under an unverified methodology, exceeding Horsham (4.4%), NHS Sussex Integrated Care Board (2.1%) and England (2.3%). Census usual residents are 91.2% White, below Horsham (93.6%), in line with NHS Sussex Integrated Care Board (91.0%) and above England (81.1%), with an 8.8% ethnic minority share. Registered patient counts differ from Census resident ethnicity bases.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Horsham local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Horsham LA) | 2,154 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.1% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 62.4% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Horsham LA) | 909 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Horsham LA) | 10.5 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 8.5 and Core20 share is 0.0% across both member practices
The PCN has an average IMD decile of 8.5, indicating low overall deprivation against Horsham (8.2), NHS Sussex Integrated Care Board (6.1) and England (5.5). Its Core20 share is 0.0% (0 patients), matching Horsham (0.0%) but below NHS Sussex Integrated Care Board (9.2%) and England (21.0%). Core20 share is 0.0% at Riverside Medical Practice (IMD decile 8.3) and 0.0% at Holbrook Surgery (decile 8.6). Area deciles do not preclude individual disadvantage among the 27,887 registered patients.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
195
SMI register
0.70% recorded prevalence
125
Learning disability register
0.45% recorded prevalence
20
Care homes, 871 beds
In the PCN catchment
8.0%
Provide unpaid care
Horsham, Census 2021
The PCN records 195 patients on the severe mental illness register (0.7%) and 125 with learning disabilities (0.5%). The catchment includes 20 care homes with 871 beds. Horsham district recorded 9 rough sleepers in 2025, while its 8.0% unpaid carer rate yields an estimated PCN ceiling of 2,231 unpaid carers. District and bed figures do not establish registered patient headcounts.
Severe mental illness: physical health checks
SMI blood pressure checks reached 85.1% (England 83.4%), yet fell 1.2 pp over 2023 to 2025 (England +4.4 pp). At Riverside Medical Practice, checks fell 7.0 pp over 2023 to 2025.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,148
Hypertension register
+2.06%
Register growth, 3 yrs
Horsham +4.65% · England +5.60%
−1.00pp
BP control, under 80
≤140/90 · +0.77pp aged 80+
+727
More patients by 2030
Forecast 4,875 (15.55%)
Hypertension case-finding and control
Hypertension recorded prevalence is 14.9% (register 4,148), below Horsham (16.8%) and England (15.2%), rising +0.3 pp over 2023 to 2025 (England +0.8 pp). Unadjusted benchmark scenarios indicate a register gap of +99 to +531 patients. Hypertensive patients with a recent blood pressure reading reach 87.6%, behind Horsham (92.0%) and England (90.0%). Blood pressure control under age 80 is 68.0%, below Horsham (71.5%) and above England (67.8%), having fallen 1.0 pp over 2023 to 2025 (England +2.1 pp). Control is 69.3% at Riverside Medical Practice and 67.0% at Holbrook Surgery. Lower control than the borough highlights an opportunity to review recall and medication titration.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reached 63.2%, below England (63.6%) and above Horsham (62.1%), following a gain of +7.7 pp over 2023 to 2025 (England +3.8 pp). Achievement was 68.8% at Riverside Medical Practice and 59.5% at Holbrook Surgery.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 28,692 | £4.00 | £2.42 | £1.86 | £114,768 |
| Cardiovascular (all), 2025 | 36,321 | £4.51 | £3.32 | £3.33 | £163,808 |
In 2026, 28,692 lipid-regulating drug items were prescribed at £4.00 per item, above Horsham (£2.64) and England (£1.86), while prescribing for persons aged 18+ was 1,280 items per 1,000 (England 4,100). Across 28,692 items, the PCN spends £61,401 more than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.78%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.92%
Asthma prevalence, PCN 3-yr % change
Asthma reviews fell 2.8% over 2023 to 2025 (England +4.4%) to 56.5%, trailing Horsham (62.4%) and England (65.7%), leaving about 720 of 1,663 patients unreviewed. Second-hand smoke recording for asthma patients aged 6-19 reached 73.4% (England 78.8%), while asthma drug prescribing for ages 5-19 was 704 per 1,000 (England 1,488). COPD reviews rose +8.4% over 2023 to 2025 (England +2.8%) to 79.2% (England 76.4%), with COPD prevalence at 1.2% (England 1.9%).
Cancer register and children's immunisation
Cancer register prevalence is 3.9% (1,072 patients), in line with England (3.8%) and below Horsham (5.1%). In childhood immunisation, age-5 MMR1 reached 100.0%, but MMR2 dropped 6.1 pp to 93.9% and the 4-in-1 booster reached 92.4%, both trailing the 95.0% target. At Riverside Medical Practice, the MMR dose drop was 10 pp, while at Holbrook Surgery it was 2.8 pp. Targeted pre-school recall is required to close second-dose immunisation gaps.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, NHS Sussex ICB diagnosed 58.5% of cancers at stage 1 or 2 among cases with a known stage (4,799 of 8,209), above England (55.3%) but 16.5 pp below the 75.0% national ambition by 2028. Staging completeness reached 64.3% (8,209 of 12,766; England 67.0%), requiring about 1,360 extra early diagnoses annually across the ICB. While ICB staging reflects wider system pathways rather than PCN performance, PCN cancer register growth (+7.9%) trailed England (+9.0%), diverging between practices: falling 2.1% at Riverside Medical Practice while rising +14.6% at Holbrook Surgery. Diverging practice trends may reflect coding differences or referral patterns (unverified locally), making register safety-netting audits an operational priority.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Surrey and Sussex Healthcare NHS Trust achieved 70.0% on the 62-day cancer standard, below the 85.0% standard by 15.0 pp, against 84.5% at Royal Surrey NHS Foundation Trust, 65.2% at University Hospitals Sussex NHS Foundation Trust, 71.5% across NHS Surrey and Sussex Integrated Care Board, and 71.2% in England. Its 28-day faster diagnosis rate reached 77.7% (standard 75.0%; England 79.3%). Diagnostic 6+ week waits were 28.5% at Surrey and Sussex Healthcare NHS Trust, above Royal Surrey NHS Foundation Trust (8.8%), University Hospitals Sussex NHS Foundation Trust (12.9%), and England (23.1%).
| Pathways within standard (%) | Surrey and Sussex Healthcare | Sussex | Royal Surrey | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.74 | 74.01 | 82.62 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.20 | 76.79 | 96.43 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 69.97 | 65.20 | 84.48 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Surrey and Sussex Healthcare | Sussex | Royal Surrey | England |
|---|---|---|---|---|
| MRI | 27.53 | 5.62 | 0.00 | 21.40 |
| CT | 18.49 | 8.57 | 0.15 | 9.92 |
| Echocardiography | 43.78 | 0.39 | 1.55 | 28.48 |
| Colonoscopy | 15.11 | 39.35 | 0.00 | 30.83 |
| Gastroscopy | 21.06 | 20.02 | 0.00 | 29.02 |
| All 15 DM01 tests | 28.50 | 12.95 | 8.82 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In Jun 2026 (provisional), West Sussex residents recorded 78,050 community care contacts across 19,770 patients, contributing to 309,615 contacts across NHS Surrey and Sussex Integrated Care Board. Contacts with adults aged 65+ accounted for 72.7% of West Sussex contacts (56,740 of 78,050). These experimental figures reflect local authority resident and system activity rather than unique PCN patient contacts.
Practice variation and patient experience
Phone access and vaccination achievement diverge by 31.5 percentage points between practices
In 2025/26, clinical QOF achievement reached 99.6% at Riverside Medical Practice and 99.5% at Holbrook Surgery (England 97.1%). Vaccination and immunisation achievement diverged by 31.5 pp, from 79.8% at Holbrook Surgery to 48.3% at Riverside Medical Practice (England 55.2%). Strong chronic disease management sits alongside marked inter-practice divergence in immunisation delivery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Holbrook Surgery | 104 | 0.0 | 78.6% | 65.5% | 91.7% |
| Riverside Medical | 122 | 0.0 | 47.0% | 55.7% | 70.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
16 of 25 measures trailed England's three-year change despite strong current review rates
Over 2023 to 2025, 16 of 25 measures trailed England's three-year change. The widest relative lags were heart failure reviews, which fell 4.9% (England +8.7%), learning disability register prevalence, falling 7.9% (England +5.4%), and dementia prevalence, down 2.4% (England +6.0%). Conversely, key strengths exceeded national gains: QRISK ≥ 20% lipid therapy grew +13.8% (England +6.2%), diabetes statin prescribing rose +8.2% (England +2.1%), and COPD reviews rose +8.4% (England +2.8%). While current heart failure review coverage remains 81.1% (England 78.5%), trailing review trajectories contrast with wider national progress.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Learning disability register
Dementia register
Asthma reviews
Alcohol record (psychosis)
QRISK statin treatment
Diabetes statin (no CVD)
COPD reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Horsham | Asset | PCN | Horsham |
|---|---|---|---|---|---|
| Care homes (catchment) | 20 (871 beds) | n/a | Schools (catchment) | 48 | n/a |
| Children's centres | 6 | 9 | Places of worship | 35 | 93 |
| Libraries | 1 | 7 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | 4 | 7 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | 1 | 2 | Primary schools (LA maintained) | 16 | 37 |
| Primary academies | 2 | 6 | Special schools | 2 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review recall
Asthma reviews reached 56.5% (register 1,663), below Horsham (62.4%) and England (65.7%), falling 2.8% over 2023 to 2025 (England +4.4%) and leaving 723 (about 720) patients unreviewed. For discussion: the PCN could run structured asthma recall using a single review template and flexible appointment slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension case-finding and register audit
Hypertension prevalence is 14.9% (register 4,148), below England (15.2%) and Horsham (16.8%), giving an unadjusted gap of +99 to +531 patients across the 27,887 list. For discussion: practices could search records for repeated raised blood pressure readings without a hypertension diagnosis code and offer opportunistic checks. Low cost, quick to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Dementia and learning disability register validation
Dementia prevalence is 0.4% (113 patients, down 2.4% vs England +6.0%; unadjusted gap +105 to +147) and learning disability is 0.5% (125, down 7.9% vs +5.4%; gap +15 to +39). For discussion: practices could audit diagnostic coding and validate registers against existing clinical and care home records. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult capacity planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Nonspatial vulnerability screening (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall audit (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall targeting (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register coding audit (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Telephony and triage workflow review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension case-finding and register audit (p12) | Hypertension register · Hypertension: QOF prevalence · Aged 65+ | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Dementia and learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Dementia register | 75% annual health checks (Network Contract DES) · Oliver McGowan · 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
